CBM light up lives mid banner advert
Advertisement: Hewitsons mid banner
Advertisement: Kao Data Centre mid banner
ARM Innovation Hub
Advertisement: Simpsons Creative
Mid banner advertisement: BDO
Advertisement – Charles Stanley mid banner
Advertisement: Cambridge Network mid banner
Advertisement: CJBS mid banner
Advertisement: Howard Group mid banner
Advertisement: EY Mid banner
Advertisement: Mogrify mid banner
Advertisement mid banner S-Tech 1
Advertisement: RSM
Barr Ellison Solicitors – commercial property
Advertisement: EBCam mid banner
8 March, 2021 - 11:08 By Tony Quested

Avacta shares leap as test detects new Covid variants

Avacta’s UK share price rose 10.50p (5.28 per cent) as its rapid antigen test was confirmed to detect SARS-CoV-2 new variants.

The Cambridge company’s AffiDX® SARS-CoV-2 lateral flow test detects both B117 'Kent' and D614G variants of the virus, it has been revealed.

AIM-quoted Avacta Group develops innovative cancer therapies and diagnostics based on its proprietary Affimer® and pre|CISION™ platforms.

The SARS-CoV-2 virus, like most viruses, mutates over time into slightly different variants. Some of these are more infectious and therefore more rapidly transmissible and have the potential to become dominant strains.

Early on in the pandemic a variant referred to as D614G appeared, which rapidly became the dominant strain globally1. The B117 variant, which was first observed in Kent, is prevalent in the UK, has been found in more than 50 countries and, according to Professor Sharon Peacock (Professor of Public Health and Microbiology at Cambridge University) is likely to become the next dominant strain globally.

Avacta has carried out analytical tests with the spike proteins isolated from both the B117 and D614G variants.

Chief executive Dr Alastair Smith said: “We are pleased to confirm that Avacta's rapid antigen test detects the B117 strain, an important variant of the SARS-CoV-2 virus and one which is especially prevalent in the UK. We have also shown that our test detects the D614G variant, the current dominant global strain.

“We will continue to monitor the performance of the Affimer reagents with future dominant variants as they become available to us.  Since the Affimer reagents we use in Avacta's range of SARS-CoV-2 tests do not bind in the region of the spike protein where the dominant mutations appear, we do not anticipate that the performance of the tests will be affected.

“Now that we have developed a robust lateral flow test architecture we can easily insert Affimer reagents that that can be very rapidly developed for new variants if necessary and indeed in response to any other future pandemic virus.

“Our next key milestone is full clinical validation and CE marking of our lateral flow antigen test which we anticipate will be around the end of this quarter and I look forward to updating the market when that milestone is achieved.”

Newsletter Subscription

Stay informed of the latest news and features